Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 5th edition, 486 pages

Free download


  Prostate Cancer

  Free Subscription


19.10.2020

1 Am J Pathol
3 BJU Int
1 BMC Cancer
1 Cancer
1 Cancer Imaging
1 Clin Cancer Res
1 Eur Radiol
1 Eur Urol
2 Int J Cancer
1 Int J Urol
1 J Clin Oncol
6 J Urol
2 Oncogene
1 Prostate


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Pathol

  1. VELLKY JE, Ricke EA, Huang W, Ricke WA, et al
    Expression, Localization, and Function of the Nucleolar Protein BOP1 in Prostate Cancer Progression.
    Am J Pathol. 2020 Oct 8. pii: S0002-9440(20)30454.
    PubMed         Abstract available


    BJU Int

  2. EXTERKATE L, Peters M, Somford DM, Vergunst H, et al
    Functional and oncological outcomes of salvage cryosurgery for radiorecurrent prostate cancer.
    BJU Int. 2020 Oct 11. doi: 10.1111/bju.15269.
    PubMed         Abstract available

  3. FUJIHARA A, Iwata T, Shakir A, Tafuri A, et al
    Multiparametric Magnetic Resonance Imaging Facilitates Reclassification During Active Surveillance for Prostate Cancer.
    BJU Int. 2020 Oct 11. doi: 10.1111/bju.15272.
    PubMed         Abstract available

  4. NAIR SM, Hatiboglu G, Relle J, Hetou K, et al
    MRI-Guided Transurethral Ultrasound Ablation in Patients with Localized Prostate Cancer: Three Year Outcomes of a Prospective Phase I Study.
    BJU Int. 2020 Oct 9. doi: 10.1111/bju.15268.
    PubMed         Abstract available


    BMC Cancer

  5. MENDEZ LC, Arifin AJ, Bauman GS, Velker VM, et al
    Is hypofractionated whole pelvis radiotherapy (WPRT) as well tolerated as conventionally fractionated WPRT in prostate cancer patients? The HOPE trial.
    BMC Cancer. 2020;20:978.
    PubMed         Abstract available


    Cancer

  6. PAKARAINEN T, Nevalainen J, Talala K, Taari K, et al
    Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC).
    Cancer. 2020 Oct 13. doi: 10.1002/cncr.33254.
    PubMed         Abstract available


    Cancer Imaging

  7. HIETIKKO R, Kilpelainen TP, Kenttamies A, Ronkainen J, et al
    Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study.
    Cancer Imaging. 2020;20:72.
    PubMed         Abstract available


    Clin Cancer Res

  8. AWASTHI S, Berglund AE, Abraham-Miranda J, Rounbehler RJ, et al
    Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer.
    Clin Cancer Res. 2020 Oct 9. pii: 1078-0432.CCR-20-2925.
    PubMed         Abstract available


    Eur Radiol

  9. GIGANTI F, Pecoraro M, Stavrinides V, Stabile A, et al
    Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study.
    Eur Radiol. 2020;30:2082-2090.
    PubMed         Abstract available


    Eur Urol

  10. CORNFORD P, van den Bergh RCN, Briers E, den Broeck TV, et al
    EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
    Eur Urol. 2020 Oct 7. pii: S0302-2838(20)30773.
    PubMed         Abstract available


    Int J Cancer

  11. HAO J, Ci X, Wang Y, Choi SYC, et al
    GRB10 sustains AR activity by interacting with PP2A in prostate cancer cells.
    Int J Cancer. 2020 Oct 10. doi: 10.1002/ijc.33335.
    PubMed         Abstract available

  12. MOLLER K, Kluth M, Ahmed M, Burkhardt L, et al
    Chromosome 5 harbors two independent deletion hotspots at 5q13 and 5q21 that characterize biologically different subsets of aggressive prostate cancer.
    Int J Cancer. 2020 Oct 12. doi: 10.1002/ijc.33344.
    PubMed         Abstract available


    Int J Urol

  13. HATAKEYAMA S, Ohyama C
    Response to Re: Geriatric 8 screening of frailty in patients with prostate cancer.
    Int J Urol. 2020 Oct 12. doi: 10.1111/iju.14399.
    PubMed        


    J Clin Oncol

  14. HUSSAIN M, Lin D, Saad F, Vapiwala N, et al
    Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?
    J Clin Oncol. 2020 Oct 13:JCO2002268. doi: 10.1200/JCO.20.02268.
    PubMed        


    J Urol

  15. MONTORSI F, Capogrosso P
    Re: The Impact of Nocturia on Mortality: A Systematic Review and Meta-AnalysisJ. S. Pesonen, R. Cartwright, R. W. M. Vernooij, Y. Aoki, A. Agarwal, A. Mangera, A. D. Markland, J. F. Tsui, H. Santti, T. L. Griebling, A. E. Pryalukhin, J. Riikonen, R. M
    J Urol. 2020;204:589-590.
    PubMed        

  16. HELFAND B
    Editorial Comment.
    J Urol. 2020;204:474-475.
    PubMed        

  17. VILLERS A, Olivier J
    Editorial Comment.
    J Urol. 2020;204:489.
    PubMed        

  18. ALGHAZO O, Cumberbatch M, Murphy DG
    Editorial Comment.
    J Urol. 2020;204:502.
    PubMed        


  19. Erratum: Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop.
    J Urol. 2020;204:1069.
    PubMed        

  20. SIEGEL C
    Re: Classification of Cancer at Prostate MRI: Deep Learning versus Clinical PI-RADS Assessment.
    J Urol. 2020;204:597.
    PubMed        


    Oncogene

  21. WANG YA, Sfakianos J, Tewari AK, Cordon-Cardo C, et al
    Molecular tracing of prostate cancer lethality.
    Oncogene. 2020 Oct 12. pii: 10.1038/s41388-020-01496.
    PubMed         Abstract available

  22. BHAGIRATH D, Liston M, Patel N, Akoto T, et al
    MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
    Oncogene. 2020 Oct 9. pii: 10.1038/s41388-020-01493.
    PubMed         Abstract available


    Prostate

  23. IWAMOTO H, Izumi K, Shimada T, Kano H, et al
    Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer.
    Prostate. 2020 Oct 13. doi: 10.1002/pros.24082.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: